Siegmund Wolf

Title: Siegmund Wolf: Innovator in Prolactin Receptor Antibodies

Introduction

Siegmund Wolf is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of neutralizing prolactin receptor antibodies. With a total of 2 patents, his work focuses on therapeutic applications that address various benign disorders.

Latest Patents

Siegmund Wolf's latest patents include the invention of neutralizing prolactin receptor antibody 006-H08. This invention encompasses maturated forms and antigen-binding fragments, along with pharmaceutical compositions that utilize these antibodies. The therapeutic use of this invention targets the treatment and prevention of conditions mediated by the prolactin receptor, such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease, and more. Additionally, he has developed another patent for neutralizing prolactin receptor antibody 005-C04, which shares similar therapeutic applications and mechanisms of action.

Career Highlights

Siegmund Wolf is associated with Bayer Intellectual Property GmbH, where he continues to innovate in the field of biotechnology. His work has the potential to significantly impact the treatment of various benign disorders, showcasing his dedication to advancing medical science.

Collaborations

Siegmund collaborates with esteemed colleagues, including Christiane Otto and Christoph Freiberg. Their combined expertise contributes to the success of their innovative projects.

Conclusion

Siegmund Wolf's contributions to the field of prolactin receptor antibodies highlight his role as a key innovator in biotechnology. His patents reflect a commitment to addressing important medical challenges through innovative solutions.